Group items tagged

Are you struggling with the fact that you really don't know anything about how to get into shape? If you're busy living in yesterday's errors, many of your decisions will be founded on guilt and shame instead of what you really want (and need) to accomplish to achieve your goals. Real change comes from day-to-day choices and becoming mindful and basing your choices on what you need now (rather than what you did or didn't do yesterday) will make your exercise life much more passable. What if I can offer you a solution that will help you to attain greatness, to become a success and learn about the best ways to get in shape? In this book, you will learn about: - Navigate the Astral Plane - MIRROR MADNESS - The Health Zen - Vitamin Vitality - Native American Healing - Boost your Health with Gua Sha - Beautiful Body Essential - Secret of Food Combination - Lose Weight Fasting - Child Diet - many other useful things!

Are you struggling with the fact that you really don't know anything about how to get into shape? If you're busy living in yesterday's errors, many of your decisions will be founded on guilt and shame instead of what you really want (and need) to accomplish to achieve your goals. Real change comes from day-to-day choices and becoming mindful and basing your choices on what you need now (rather than what you did or didn't do yesterday) will make your exercise life much more passable. What if I can offer you a solution that will help you to attain greatness, to become a success and learn about the best ways to get in shape? In this book, you will learn about: - Navigate the Astral Plane - MIRROR MADNESS - The Health Zen - Vitamin Vitality - Native American Healing - Boost your Health with Gua Sha - Beautiful Body Essential - Secret of Food Combination - Lose Weight Fasting - Child Diet - many other useful things!

P3 Healthcare Solutions is been offering professional medical billing services for quite some time now. The process starts from the consultation session where providers are informed about every detail from coding, billing to the latest strategies for smoothly running the revenue cycle. We aim to empower physicians with transparent and accurate billing practices.

Under MIPS QPP (Quality Payment Program), physicians report clinical data to CMS. They reward clinicians upon their contribution to make the current healthcare system an empowered one, incorporating technology and interoperability for patients' convenience.

This is not a recent breakthrough, but in our complicated world of new ideas, simplicity is often overlooked. This article points out that magnesium deficiency is a major problem and I think symptoms stemming from magnesium deficiency can be easily overlooked. The article acknowledges an extensive list of symptoms that seem to be rampant in our society. They are: constipation, high blood pressure (hypertension), anxiety, depression insomnia, behavioral disturbances, lethargy impaired memory/thinking, seizures, fatigue, sleep disturbances, pain, muscle cramps, chronic back pain, headaches, migraines, muscular pain, tendonitis, anger, aggression, ADHD, brain fog, tension, anxiety disorders such as OCD. Sounds familiar? What I think is important about this is article is that before we move on to more complex and expensive solutions for any of these problems, we might want to begin with a simple high quality magnesium supplement of your choice. I take it personally, and see the benefits of it in my own ability to rest and focus. Good mechanics always recommend beginning with the simplest solution first, and if that doesn't work, then work your way up to more expensive theories to solve the problem. Today, people often begin with the most expensive theory because they could feel that because their problem is complicated to them, the solution is not simple and they expect to pay more. This is subjective. I suppose the same strategy could be be applied to health.

Finding solutions to bring those worry-levels down for healthcare professionals can put an end to burnout and improve the quality of care altogether. Physicians are as humans as us, and in this article, we discuss ways in which they can deal with guilt and shame when they fail to complete their tasks of the day.

P3care Solutions has its finger on the pulse of healthcare, at least that's what we intend to achieve. The topic that we chose to write about today has some interesting yet solid statistics of doctors and their time spent on EHRs per patient.

P3care Solutions has its finger on the pulse of healthcare, at least that's what we intend to achieve. The topic that we chose to write about today has some interesting yet solid statistics of doctors and their time spent on EHRs per patient.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 medicines recall for Sabril 500 mg film-coated tablets & Sabril 500 mg granules for oral solution. Sanofi UK has recalled the batches of Sabril tablets and Sabril granules as a precautionary measure due to the detection of traces of tiapride in the batches of the source material of the manufacturer for vigabatrin. Sabril (vigabatrin) is indicated for adjunctive treatment of focal seizures with or without secondary generalisation not satisfactorily controlled with other antiepileptics (under expert supervision) and monotherapy in the treatment of infantile spasms (West's syndrome). All patients are advised not to discontinue Sabril tablets or Sabril granules without consulting with their prescriber. The risks of suddenly stopping medication for seizures/epilepsy is higher than the potential risk presented by the presence of tiapride. Sanofi UK have confirmed to DHSC that no other batches are impacted, and other stock remains available.

Bristol-based Titan PMR, a technology firm specialising in PMR systems for community pharmacies, is set to roll out an innovative platform named 'Titanverse,' that it claims will redefine pharmacy management, offering comprehensive solutions extending beyond prescription management. This new platform takes a versatile approach, efficiently managing all facets of pharmacy operations, from high-level management down to daily tasks, according to top company officials. "Our aim is to reshape pharmacies into genuine health hubs, providing advanced services and harnessing state-of-the-art technologies," said Tariq Muhammad, CEO of Titan PMR. "Titanverse, our latest offering, is positioned to ignite this transformation, revolutionising clinical services in the same way its predecessor revolutionised dispensing. With Titanverse, we have the vehicle to drive this vision forward, placing pharmacies at the forefront of primary care in the future." Titanverse adopts a Teams approach, catering to pharmacies with multiple locations or specific focuses. It furnishes real-time analytics and employs a color-coded rating system for swift performance evaluation. Moreover, the platform eases operations by enabling task delegation, encompassing clinical checks and dispensing, all while backing private services with adaptable templates and workflows.

AmerisourceBergen, a leading pharmaceutical solutions organisation announced its intent to change its name to 'Cencora' to better reflect its bold vision and purpose-driven approach to creating healthier futures. Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen said: "Over time, we have established ourselves as a trusted industry partner that prioritizes innovation, advocates for patient access and advances strategic partnerships across the global pharmaceutical supply chain. To further bolster our position, we must continue to adapt and evolve within our dynamic industry as we pursue the goal of enhancing health outcomes. Building a unified brand is fundamental to our identity as a global healthcare company. We believe our new name better reflects who we are today and our impact across pharmaceutical care." AmerisourceBergen intends to begin operating as Cencora in the second half of calendar year 2023. The change to Cencora is aligned with the organisation's growth strategy and continued emphasis on innovation. AmerisourceBergen has focused on supporting pharmaceutical advancement and access for patients, manufacturers, and providers across the global healthcare supply chain.

MedAdvisor will be investing $1.9 million (£1 million) into UK-based pharmacy dispensary app Charac, while securing a 7.4 per cent shareholding in the later company. Under this new agreement, MedAdvisor CEO Rick Ratliff will become a Non-Executive Director (NED) on the board of Charac. Both MedAdvisor and Charac provide digital medication adherence solutions that allow customers to file prescription orders to their local pharmacy through mobile apps. The investment is seen as part of MedAdvisor's cost saving strategy, as the Australian company has decided to discontinue its UK operations, and transfer its existing pharmacy relationships to Charac.

American healthcare technology company Omnicell has appointed Edward Platt as the new Senior Commercial Director of its UK community pharmacy division. Along with this new role, Edward, who joined Omnicell in 2015, will continue his current leadership remit for Omnicell's UK & Ireland hospital division. He will be leading a revamped commercial team, which would be responsible for increasing Omnicell's footprint of automation and consumable solutions delivered into UK community pharmacies. As part of the revamp, the company has created dedicated specialist teams to ensure the needs and challenges of community pharmacists (small independents and small multiple operators) can be fully understood and supported.

The UK Government is investing £100 million to accelerate the use of AI in life sciences and healthcare under a new mission. UK Prime Minister Rishi Sunak announced the AI Life Sciences Accelerator Mission in his speech last week. The new initiative will capitalise on the UK's unique strengths in securing "health data and cutting-edge AI." It will also help to identify those at risk of "dementia" and will ensure that patients participate in the trials at the right time to develop new treatments effectively. Henceforth, it will provide us with better data on how well new therapies work. Sunak said: "AI can help us solve some of the greatest social challenges of our time. AI could help find novel dementia treatments or develop vaccines for cancer."

Royal Pharmaceutical Society (RPS) Scotland has submitted its evidence to the Health, Social Care and Sport Committee's inquiry into 'Healthcare in remote and rural areas.' The Committee had sought views on what policies and actions would be most effective in addressing the issues people face when accessing healthcare in these areas. During the evidence session today (19 December), Laura Wilson, Director for RPS Scotland, highlighted the challenges faced by pharmacists and pharmacy in remote and rural areas, as well as provided some of the solutions for ensuring a sustainable pharmacy workforce. At present, people living in remote and rural areas of Scotland are required to travel to Glasgow or Aberdeen to undertake pharmacy training. Laura underscored the need to develop alternative education and training pathways, such as "grow your own" models, to support remote and rural areas to develop and retain local pharmacists.

Levomepromazine 25mg/1ml solution for injection will remain unavailable until the week commencing March 7,2022, Department of Health and Social Care (DHSC) said in an update. While alternative medicines for use in palliative care remain available in ample supply to support an uplift in demand, the date supply resumption of Levomepromazine is yet to be confirmed. The DHSC has sent a copy of this medicine supply notification to all pharmacy NHS email addresses. It further informed primary care providers that prescription validation has been temporarily implemented at wholesaler level.

Hospitals and healthcare providers across the UK have been notified about the shortage of an anti-inflammatory medicine caused by a manufacturing failure. The Department of Health and Social Care (DHSC) on Friday (3 May) issued a National Patient Safety Alert stating that Erelzi 50mg solution for injection in pre-filled pen will be out of stock from early May until mid-July 2024. "The supply issues have been caused by a manufacturing failure resulting in delays in production and the implementation of global allocations," it said. However, it noted that homecare providers (Alcura, Healthnet and Sciensus) have sufficient stock to supply existing patients until mid/late May 2024. Although Erelzi 50mg pre-filled syringes (PFS) are still available, they cannot support a full increase in demand, the DHSC warned.

The latest formulation of XGEVA (denosumab) is now available to patients in the UK, offering a more convenient treatment option for bone metastasis. It is the first product to be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) via the new International Recognition Procedure (IRP). Denosumab (XGEVA) is used to prevent serious bone-related complications resulting from bone metastasis in adults and to treat giant cell tumour of bone in both adults and adolescents. The medicine was authorised on 29 February 2024 as a 120 mg solution for injection in a prefilled syringe. In contrast to the current vial presentation, this simplifies the administration process, reducing the volume of liquid injected and lowering the risk of dosing errors. The product was authorised in 30 days by the MHRA, thanks to the new IRP that facilitated a rapid approval process.

A recent study, conducted by CBD experts at Brown's CBD, unveiled Dundee as the UK's leading CBD hotspot, with an average monthly search volume of 530.29 per 100,000 residents, sparking a surge of interest in natural wellness solutions. New research analysed search volume data across UK cities for CBD-related terms, reflecting a staggering 1100% increase in searches for 'what is CBD' over the last decade. Following Dundee, Brighton secures the second spot in the rankings with an average monthly search volume of 530.08 per 100,000 residents for CBD related terms, closely trailed by St. Albans in third place. Other notable cities making the top ranks include Gloucester, Hereford, and Bath, indicating a widespread curiosity about CBD products and their purported health benefits.

The National Health Services England (NHSE) is poised to revolutionise diabetes management with the introduction of the 'artificial pancreas', also known as the Hybrid Closed Loop system, to treat type 1 diabetes. This pioneering initiative, endorsed by the National Institute of Health Care and Excellence (NICE), represents a global first in healthcare innovation. With 269,095 individuals grappling with type 1 diabetes in England, the Hybrid Closed Loop system is set to cater to tens of thousands of children and adults across the nation. This cutting-edge device operates by seamlessly monitoring blood glucose levels and autonomously adjusting insulin dosage through a pump, by eliminating the need for regular insulin injections. Furthermore, it holds the promise of averting life-threatening hypoglycaemic and hyperglycaemia episodes, mitigating significant risks associated with the condition. To facilitate the identification of beneficiaries, NHSE has allocated a substantial sum of £2.5 million, ensuring that those who could benefit from this innovative solution receive the necessary support.

Seven NHS trusts in England are set to begin trials of new wireless technologies to help improve patient care and strengthen connectivity in A&Es and ambulance bays. They have been awarded around £1 million as part of NHS England's Wireless Trials programme, which aims to leverage advanced wireless technologies to enhance patient care and experiences while freeing up more staff time. Manchester University NHS Foundation Trust will introduce an innovative approach of combining satellite and cloud-based wireless solutions to enhance connectivity across its 10 hospital sites and wider community services. At Mid Cheshire and Princess Alexandra Hospital NHS trusts, wireless trackers will be installed on medical equipment and hospital beds. This will allow real-time monitoring and location tracking, enabling easy accessibility for staff to locate necessary items promptly.

A new study has underscored the significance of offering customers a variety of payment choices, particularly as digital platforms gain popularity among younger age groups. Almost one in three (30 per cent) people surveyed by payments solutions provider, Access PaySuite reported a negative experience when purchasing health and wellbeing products or services due to limited payment options. The research showed that online and in-person cash payments were the most preferred modes of payment, while more than a quarter of consumers expressed their preference for paying through Direct Debit. About 17 per cent of the participants favoured using a mobile app for payments during the booking process, followed by mobile in-person options like Google Pay (14 per cent) and phone-based transactions using debit or credit card) (13 per cent).

The Medicines and Healthcare products Regulatory Agency (MHRA) has reclassified codeine linctus, a medicine used for the treatment of dry cough, from a pharmacy-only medicine (P) to a prescription-only medicine (POM) owing to the risk of dependence, addiction, and overdose. This implies that the dry cough syrup, which is also known as codeine oral solution, can only be dispensed upon the submission of a prescription at a pharmacy, rather than being accessible over the counter upon request. Patients are cautioned that as an opioid medicine, codeine can be addictive, and the risk of addiction may increase, particularly with prolonged use over an extended period. According to the medicines regulator, codeine is converted into morphine by the liver enzyme CYP2D6. In individuals identified as ultra-rapid metabolizers, this conversion from codeine to morphine occurs at a faster rate than in others. "If you want to stop taking it and have been taking codeine linctus for a long time, then it is important to reduce the amount you take slowly with the help of your prescriber," the agency said in its drug safety update issued on Tuesday, 20 February.